Physician profile
Therese Javier
NPI 1932814944
$2,620.24
in general payments reported to CMS, 2019-2025
28 companies · $2,552 in 2025
The $2,552 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $68.44 · 2025: $2,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,542 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,542.25 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $393.76 | 2025 | Rybrevant, Carvykti, Darzalex |
| Merck Sharp & Dohme LLC | $372.33 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Abbvie INC. | $225.65 | 2025 | Imbruvica, Elahere, Venclexta |
| Sobi, INC | $192.94 | 2025 | Doptelet, Vonjo, Gamifant |
| Astellas Pharma US INC | $187.32 | 2025 | Vyloy |
| Eisai INC. | $153.13 | 2025 | Lenvima |
| Beone Medicines USA, INC. | $123.28 | 2025 | Brukinsa, Tevimbra |
| Takeda Pharmaceuticals U.S.A., INC. | $107.84 | 2025 | Fruzaqla |
| Puma Biotechnology, INC. | $83.48 | 2025 | Nerlynx |
| Astrazeneca Pharmaceuticals LP | $69.96 | 2024-2025 | |
| Genzyme Corporation | $68.68 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.56 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.31 | 2025 | |
| Lilly USA, LLC | $59.74 | 2025 | Verzenio, Jaypirca |
| Daiichi Sankyo INC. | $58.17 | 2025 | Enhertu, Vanflyta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $43.51 | 2025 | Tevimbra, Brukinsa |
| Alexion Pharmaceuticals, INC. | $40.99 | 2024 | Ultomiris |
| Agios Pharmaceuticals, INC. | $39.89 | 2025 | Pyrukynd |
| Servier Pharmaceuticals LLC | $39.62 | 2025 | Tibsovo |
| Incyte Corporation | $34.73 | 2025 | Jakafi |
| Taiho Oncology, INC. | $34.42 | 2025 | Inqovi, Lonsurf |
| Regeneron Healthcare Solutions, INC. | $32.69 | 2025 | Libtayo |
| Celgene Corporation | $27.20 | 2025 | Reblozyl |
| Amneal Pharmaceuticals LLC | $24.56 | 2025 | Pemrydi Rtu |
| Emd Serono, INC. | $23.48 | 2025 | |
| Spectrum Pharmaceuticals INC. | $20.04 | 2025 | Rolvedon |
| E.R. Squibb & Sons, L.L.C. | $19.10 | 2025 | |
| Accord Healthcare, INC. | $16.86 | 2025 | Camcevi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Therese Javier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.